Open AccessA multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
Author(s) -
Hoyles Rachel K.,
Ellis Ross W.,
Wellsbury Jessica,
Lees Belinda,
Newlands Pauline,
Goh Nicole S. L.,
Roberts Christopher,
Desai Sujal,
Herrick Ariane L.,
McHugh Neil J.,
Foley Noeleen M.,
Pearson Stanley B.,
Emery Paul,
Veale Douglas J.,
Denton Christopher P.,
Wells Athol U.,
Black Carol M.,
du Bois Roland M.
Publication year - 2006
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.22204
Subject(s) - dlco , medicine , placebo , pulmonary fibrosis , randomized controlled trial , idiopathic pulmonary fibrosis , pulmonary function testing , azathioprine , diffusing capacity , scleroderma (fungus) , cyclophosphamide , vital capacity , prednisolone , gastroenterology , surgery , lung , chemotherapy , pathology , lung function , alternative medicine , disease , inoculation
Objective The lack of randomized controlled trials (RCTs) in pulmonary fibrosis in systemic sclerosis (SSc) has hampered an evidence‐based approach to treatment. This RCT was undertaken to investigate the effects of intravenous (IV) cyclophosphamide (CYC) followed by azathioprine (AZA) treatment in pulmonary fibrosis in SSc. Methods Forty‐five patients were randomized to receive low‐dose prednisolone and 6 infusions (monthly) of CYC followed by oral AZA, or placebo. Primary outcome measures were change in percent predicted forced vital capacity (FVC) and change in single‐breath diffusing capacity for carbon monoxide (DL CO ). Secondary outcome measures included changes in appearance on high‐resolution computed tomography and dyspnea scores. An intent‐to‐treat statistical analysis was performed. Results At baseline, there were no significant group differences in factors linked to outcome, including severity of pulmonary fibrosis and autoantibody status. Sixty‐two percent of the patients completed the first year of treatment. Withdrawals included 9 patients (6 from the placebo group) with significant decline in lung function, 2 with treatment side effects (both from the active treatment group), and 6 with non–trial‐related comorbidity. No hemorrhagic cystitis or bone marrow suppression was observed. Estimation of the relative treatment effect (active treatment versus placebo) adjusted for baseline FVC and treatment center revealed a favorable outcome for FVC of 4.19%; this between‐group difference showed a trend toward statistical significance ( P = 0.08). No improvements in DL CO or secondary outcome measures were identified. Conclusion This trial did not demonstrate significant improvement in the primary or secondary end points in the active treatment group versus the group receiving placebo. However, for FVC there was a trend toward statistical significance between the 2 groups. This suggests that treatment of pulmonary fibrosis in SSc with low‐dose prednisolone and IV CYC followed by AZA stabilizes lung function in a subset of patients with the disease. Therapy was well tolerated with no increase in serious adverse events.